FDA: Ra-223 suspended until further notice

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Due to manufacturing delays and shortage in supply, Ra-223, aka Xofigo, is currently not available, the FDA announced Oct. 7.

Neither the FDA nor the drug’s maker, Bayer Healthcare, have released an estimated date for when supply of Ra-223 will be restored.

Ra-223 dichloride injection is an oncologic therapeutic originally FDA-approved in May of last year for castration-resistant metastatic prostate cancer to the bone with no known visceral metastatic disease.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.